While loss-of-function mutations suggest a tumor suppressor role for RUNX1, RUNX1 was reported to reinforce the TAL1-driven oncogenic program in T-cell acute lymphoblastic leukemia [12]. This evidence concerns the gene RUNX1 and neoplasm.